Who should be transplanted for AML?
- 1 April 2001
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 15 (4), 680-682
- https://doi.org/10.1038/sj.leu.2402074
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First RemissionThe New England Journal of Medicine, 1998
- Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trialThe Lancet, 1998
- T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host DiseaseBlood, 1998
- Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysisBone Marrow Transplantation, 1997
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaThe New England Journal of Medicine, 1995
- Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.Journal of Clinical Oncology, 1992
- Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapyBlood, 1992
- Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapyBlood, 1992
- Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapseBlood, 1983